Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antipsychotic

or Anxiolytic

or Phenethylamine

Use the filters below to narrow your results.

None (29) · Clozaril (1) · Compazine (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Lexotan (1) · Librium (1) · Loxitane (1) · Mellaril (1) · Miltown (1) · Moban (1) · Navane (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Orap (1) · Prolixin (1) · Saphris (1) · Serax (1) · Stelazine (1) · Thorazine (1) · Tranxene (1) · Trilafon (1) · Xanax (1) · Zoloft (1)

5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA modulator; glycine receptor agonist (1) · GABAA positive allosteric modulator (5) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · Kavalactones; GABAA modulator; sigma receptor activity (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multi-receptor antagonist; low D2 affinity (1) · Phenothiazine D2 antagonist (5) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Thioxanthene D2 antagonist (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Very potent 5-HT2A agonist; long duration (1)

None (53) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)

None (53) · 0.25 mg (1) · 25 mg (1)

None (53) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)

None (53) · 10 mg/d (1) · 200 mg/d (1)

None (51) · insufflated (1) · Oral (4) · PR (1)

None (51) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 45-75 min (oral) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (51) · 4-8 h (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · Chronic daily dosing (1) · Long (1)

None (51) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · Not well characterized (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (51) · 80-90% oral (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Not well characterized (1) · ~50% (highly variable) (1)

None (51) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Not established (1)

None (51) · Rx-only (1) · Rx-only in US (1) · Schedule IV (US) (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)